Eli Lilly Halts Experimental Weight Loss Trial

about 1 month ago

Bailey Lipscholz

"Eli Lilly, the drug maker, down about 1%. This comes after news that the company halted a study of an experimental drug that would be done in combination with one of its weight loss drugs to help prevent obese patients from losing too much muscle."

Eli Lilly has stopped a clinical study involving an experimental drug combination aimed at preventing muscle loss in obese patients undergoing weight loss. The decision comes as the stock trades down modestly by around 1% and near its lowest levels in recent weeks. The halting of the trial represents a re-evaluation of its strategy in a competitive field with peers like Novo Nordisk.

Related Stocks